GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (STU:4AJ0) » Definitions » Cyclically Adjusted PS Ratio

Alk-Abello AS (STU:4AJ0) Cyclically Adjusted PS Ratio : 8.88 (As of May. 24, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Alk-Abello AS Cyclically Adjusted PS Ratio?

As of today (2025-05-24), Alk-Abello AS's current share price is €22.10. Alk-Abello AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €2.49. Alk-Abello AS's Cyclically Adjusted PS Ratio for today is 8.88.

The historical rank and industry rank for Alk-Abello AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:4AJ0' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.75   Med: 6.83   Max: 11.89
Current: 8.84

During the past years, Alk-Abello AS's highest Cyclically Adjusted PS Ratio was 11.89. The lowest was 2.75. And the median was 6.83.

STU:4AJ0's Cyclically Adjusted PS Ratio is ranked worse than
66.53% of 499 companies
in the Biotechnology industry
Industry Median: 5.41 vs STU:4AJ0: 8.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alk-Abello AS's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.922. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.49 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alk-Abello AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Cyclically Adjusted PS Ratio Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.12 11.72 5.84 5.85 8.50

Alk-Abello AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 8.49 9.34 8.50 7.22

Competitive Comparison of Alk-Abello AS's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Alk-Abello AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Cyclically Adjusted PS Ratio falls into.


;
;

Alk-Abello AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alk-Abello AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.10/2.49
=8.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Alk-Abello AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.922/120.2000*120.2000
=0.922

Current CPI (Mar. 2025) = 120.2000.

Alk-Abello AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.351 100.300 0.421
201509 0.433 100.200 0.519
201512 0.456 99.800 0.549
201603 0.555 100.200 0.666
201606 0.505 100.600 0.603
201609 0.434 100.200 0.521
201612 0.506 100.300 0.606
201703 0.539 101.200 0.640
201706 0.472 101.200 0.561
201709 0.451 101.800 0.533
201712 0.476 101.300 0.565
201803 0.463 101.700 0.547
201806 0.452 102.300 0.531
201809 0.343 102.400 0.403
201812 0.489 102.100 0.576
201903 0.529 102.900 0.618
201906 0.479 102.900 0.560
201909 0.455 102.900 0.531
201912 0.530 102.900 0.619
202003 0.580 103.300 0.675
202006 0.466 103.200 0.543
202009 0.467 103.500 0.542
202012 0.603 103.400 0.701
202103 0.627 104.300 0.723
202106 0.556 105.000 0.636
202109 0.573 105.800 0.651
202112 0.660 106.600 0.744
202203 0.667 109.900 0.730
202206 0.669 113.600 0.708
202209 0.549 116.400 0.567
202212 0.691 115.900 0.717
202303 0.712 117.300 0.730
202306 0.693 116.400 0.716
202309 0.636 117.400 0.651
202312 0.763 116.700 0.786
202403 0.859 118.400 0.872
202406 0.824 118.500 0.836
202409 0.831 118.900 0.840
202412 0.918 118.900 0.928
202503 0.922 120.200 0.922

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello AS  (STU:4AJ0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alk-Abello AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Industry
Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines